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INTRODUCTION
Vitamin D affects various parts of the body, including the 
musculoskeletal, cardiovascular, and neurocognitive systems. 
It is also related to mental health. Low vitamin D level is asso-
ciated with various psychiatric illnesses, including depression, 
dementia, and autism spectrum disorder.1-4 Vitamin D levels 
are low in patients with schizophrenia. In one study, the prev-
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alence of vitamin deficiency/insufficiency was 92.5% in pa-
tients in the acute phase of schizophrenia.5 The level of vitamin 
D also affects symptom severity in patients with schizophre-
nia.6,7 Levels of vitamin D in utero predict later risk for schizo-
phrenia.8 
Low vitamin D level is independently associated with all-
cause mortality in the general population.9 In particular, low 
vitamin D is associated with cardiovascular disease.10 In a 10-
year follow-up study, male patients without previous cardio-
vascular disease and vitamin D deficiency [25(OH)D<15 ng/
mL] exhibited a twofold increase in the rate of myocardial in-
farction.11 Participants in the Framingham Offspring Study 
who had no history of cardiovascular disease but a severe vita-
min D deficiency [25(OH)D<10 ng/mL] had a hazard ratio of 
1.8 (95% confidence interval, 1.05–3.08) for developing new 
cardiovascular disease after a 5-year follow-up compared to 
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participants who had higher levels of 25(OH)D (>15 ng/mL), 
although the direction of the association remains uncertain.10
However, evidence demonstrating an association between 
vitamin D and physical health in patients with schizophrenia 
is scarce. Patients with schizophrenia die 10–20 years earlier 
than the general population.7 This premature mortality is at-
tributed to high comorbid physical illnesses, including car-
diovascular disease and metabolic syndrome.12,13 Thus, it is 
important to understand the effect of vitamin D on the physi-
cal health of patients with a psychotic disorder. 
Vitamin D levels vary according to ethnicity. They were 
shown to be relatively high in Caucasians compared to those 
in Mexican-Americans and African-Americans.14 In addition, 
vitamin D level also varies from region to region.15 Asians, in-
cluding Japanese and Koreans, show low vitamin D levels dur-
ing summer and winter compared to people in other coun-
tries.16,17 Thus, vitamin D levels must be studied in various 
regions and ethnicities. In this study, we investigated the rela-
tionship between vitamin D level and metabolic syndrome in 
Korean patients with psychotic disorders.
METHODS
Participants
The present study used the data set from Gwangju Compre-
hensive Health Inspection for Mental Illness, which evaluat-
ed the physical health of patients with mental illness (psy-
chotic and mood disorders) treated in community mental 
health centers in Gwangju, South Korea. The present study 
used data from patients who were treated for a psychotic dis-
order and excluded patients with a mood disorder. Of the 
386 participants in the parent study, 302 with a psychotic dis-
order were included in the present study, of which 248 (82.1%) 
had schizophrenia, 36 (11.9%) had schizoaffective disorder, 
and 18 (6.0%) had other specified schizophrenia spectrum 
disorder. This study was conducted from November 2015 to 
January 2016 and was approved by Chonnam National Uni-
versity Hospital’s Institutional Review Board (CNUH-2015-
254). All subjects provided written informed consent before 
participating.
Measures
Basic demographic and clinical information was obtained 
from medical records and case managers and included psy-
chiatric diagnoses, treatment duration, prescribed medications 
and dosages, depressive symptoms, physical activities, and di-
etary habits. Risperidone-equivalent doses were calculated to 
assess dose-dependent drug effects.18
The Clinical Global Impression (CGI) Scale was adminis-
tered by case managers to evaluate global symptom severity.19 
Depressive symptoms were measured by four items from the 
Center for Epidemiological Studies Depression Scale (both-
ered by things, poor appetite, feel blue, and feel depressed).20 
Physical activity was measured by three items from the Inter-
national Physical Activity Questionnaire (IPAQ)-Short Form 
(vigorous physical activity, moderate physical activity, and 
walking).21 Physical activity was determined by the type of 
exercise and time according to the IPAQ scoring protocol.22 
Dietary habits were evaluated with the dietary guidelines 
published by the Korean Ministry of Health and Welfare.23 The 
dietary questionnaire consisted of three subcategories includ-
ing five items for diet regularity, six items for a balanced diet, 
and nine items for unhealthy diet and habits. In the balanced 
diet category, the dairy intake item was also used as a proxy 
variable for vitamin D intake. We asked how many times par-
ticipants took milk and dairy products every week. 
Fasting venous blood samples were obtained to assess vita-
min D levels; lipid profiles including high-density-lipopro-
tein (HDL) cholesterol, low-density-lipoprotein cholesterol, tri-
glycerides, and total cholesterol; fasting blood glucose (FBG); 
glycated hemoglobin, liver function tests including aspartate 
aminotransferase (AST), alanine transaminase (ALT), and 
gamma-glutamyltransferase; renal function tests, including 
blood urea nitrogen and creatinine; and prolactin. Blood pres-
sure including systolic blood pressure and diastolic blood pres-
sure was also measured. Body mass index was calculated as 
weight/height2 (kg/m2). 
Metabolic syndrome was diagnosed with the definitions of 
the modified ATP III for Korea (three or more of the following 
five criteria): abdominal obesity, defined as a waist circumfer-
ence ≥90 cm in men and ≥85 cm in women24; serum triglyc-
erides ≥150 mg/dL (1.7 mmol/L) or drug treatment for ele-
vated triglycerides; serum HDL cholesterol<40 mg/dL (1 
mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or 
drug treatment for low HDL cholesterol; blood pressure ≥130/ 
85 mm Hg or drug treatment for elevated blood pressure; and 
FPG ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevat-
ed blood glucose. 
Statistical analysis
The participants were categorized into two groups accord-
ing to vitamin D level. Vitamin D insufficiency was defined as 
<20 ng/mL (equivalent to <50 nmol/L) and a serum level ≥20 
ng/mL (equivalent to ≥50 nmol/L) was considered optimal.25 
Comparisons of demographic and clinical data according 
to the presence of vitamin D insufficiency were conducted with 
the χ2 test, independent t-test, or Mann-Whitney U-test, as ap-
propriate. We examined the relationship between serum vi-
tamin D insufficiency and metabolic syndrome using logistic 
regression analysis after controlling for physical activity and 
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dietary habits. The statistical analysis was performed using 
SPSS for Windows ver. 23.0 (IBM Corp., Armonk, NY, USA). 
All statistical tests were two-sided, and the α-level for statisti-
cal significance was 0.05.
RESULTS
Among the 302 participants, 168 (55.6%) were males and 
134 were females. Their mean age was 40.7±12.0 years (range 
18–82 years) and mean duration of illness was 14.5±10.0 years. 
Mean vitamin D level was 15.5±6.4 ng/mL, and 236 patients 
(78.1%) had a vitamin D insufficiency (<20 ng/mL). Ninety-
seven patients (32.1%) met the criteria for metabolic syn-
drome. Vitamin D level was significantly lower in patients with 
metabolic syndrome than in those without metabolic syn-
drome (13.1±5.0 ng/mL vs. 16.6±6.7 ng/mL; t=4.616, p<0.001). 
Table 1 shows the demographic and clinical characteristics 
according to the presence of vitamin D insufficiency. Age, sex, 
Table 1. Baseline demographic and clinical characteristics according to vitamin D level
Vitamin D level
p-value*
<20 ng/mL, N=236 (78.1%) ≥20 mg/mL, N=66 (21.9%)
Sociodemographic characteristics
Sex, male (%) 128 (54.2) 40 (60.6) 0.402
Age, mean (SD), years 41.0 (12.0) 40.0 (12.1) 0.388
Duration of treatment, mean (SD), years 14.4 (10.1) 14.7 (9.7) 0.858
Body mass index, mean (SD), kg/m2 26.0 (4.8) 25.2 (4.5) 0.212
Waist circumference, mean (SD), cm 84.0 (11.4) 81.6 (10.4) 0.143
Clinical characteristics
Metabolic syndrome, yes (%) 85 (36.0) 12 (18.2) 0.006
Hypertension, yes (%) 79 (33.5) 12 (18.2) 0.017
Diabetes mellitus, yes (%) 120 (50.8) 26 (39.4) 0.100
Clinical Global Impression, mean (SD) 3.7 (1.1) 3.9 (1.2) 0.133
Depressive symptoms, mean (SD) 6.5 (2.9) 6.5 (2.6) 0.923
Dosage of antipsychotics, mean (SD), mg 4.8 (4.3) 4.7 (3.4) 0.069
Physical activity, mean (SD), METS 604.1 (591.5) 662.3 (588.0) 0.491
Diet habit (SD)
Total score 41.7 (6.7) 42.4 (6.7) 0.511
Balanced diet score 9.9 (2.7) 10.3 (3.5) 0.325
Regular diet score 10.5 (3.2) 11.1 (3.3) 0.158
Healthy and diet score 21.3 (3.3) 20.8 (3.4) 0.342
Dairy intake score 3.6 (1.2) 3.8 (1.4) 0.244
Laboratory characteristics
Vitamin D level, mean(SD), ng/mL 12.8 (4.0) 24.8 (4.6) <0.001
Fasting plasma glucose, mean (SD), mg/dL 108.3 (39.0) 102.5 (30.7) 0.276
HbA1c, mean (SD), % 5.9 (3.5) 5.5 (0.74) 0.354
Total cholesterol, mean (SD), mg/dL 182.6 (39.4) 175.1 (32.8) 0.158
Triglyceride, mean (SD), mg/dL 150.6 (104.6) 108.8 (68.8) 0.002
High-density lipoprotein, mean (SD), mg/dL 46.1 (11.2) 47.8 (9.8) 0.278
Low-density lipoprotein, mean (SD), mg/dL 107.7 (33.7) 106.1 (29.4) 0.734
AST mean (SD), mg/dL 24.9 (18.1) 22.8 (10.1) 0.356
ALT, mean (SD), mg/dL 29.7 (31.6) 22.2 (17.0) 0.011
γ-GTP, mean (SD), mg/dL 36.1 (34.3) 34.4 (37.8) 0.732
Blood Urea Nitrogen, mean (SD), mg/dL 84.1 (17.0) 88.0 (13.1) 0.094
Creatinine, mean (SD), mg/dL 1.0 (0.5) 1.0 (0.1) 0.444
Prolactin, mean (SD), mg/dL 41.8 (43.5) 42.2 (50.0) 0.952
Bold font denotes statistical significance. *χ2 test, t-test, or Mann-Whitney U test as appropriate. SD: standard deviation, AST: aspartate ami-
notransferase, ALT: alanine transaminase, γ-GTP: gamma-glytamyltransferase  
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and illness duration were not different according to vitamin 
D insufficiency. Metabolic syndrome and hypertension were 
significantly more frequent and levels of triglycerides and ALT 
were significantly higher in patients with a vitamin D insuffi-
ciency than in those without a vitamin D insufficiency. Values 
of other laboratory measures were not different based on the 
presence of a vitamin D insufficiency. Scores on the CGI, the 
depression scale, IPAQ, and the dietary questionnaire were 
also not different according to vitamin D insufficiency. 
Table 2 shows the results of the logistic regression analysis. 
Vitamin D insufficiency was significantly associated with met-
abolic syndrome and hypertension. After adjusting for physi-
cal activity and dietary habit scores, vitamin D insufficiency 
remained significantly associated with metabolic syndrome 
and hypertension. 
DISCUSSION
Vitamin D deficiency is considered a major health issue 
worldwide, although its significance is uncertain.17 This also 
applies to the psychiatric field.3 In general medicine, the link 
between Vitamin D and medical comorbidity has shifted from 
being seen as causative to being a proxy marker of lifestyle is-
sues, highlighted by the failure of many treatment trials to 
influence the targeted disorder.26 The present study demon-
strated that vitamin D insufficiency was highly prevalent 
(78.1%) in patients with a psychotic disorder and was associ-
ated with metabolic syndrome and hypertension. The high 
prevalence of vitamin D insufficiency in our population with 
a psychotic disorder was compatible with previous studies con-
ducted in western countries.3,27 The prevalence of vitamin D 
insufficiency in this community-dwelling psychotic popula-
tion was higher than that in the general South Korean popu-
lation. A recent South Korean study of 17,252 health examin-
ees showed that 60.4% (47.3% in males and 64.5% in females) 
of examinees had a vitamin D insufficiency (<20 ng/mL).28 
The prevalence of metabolic syndrome in this study was 
32.1%, which is higher than that in the South Korean general 
population.29,30 We also observed that metabolic syndrome 
components, such as hypertension and high triglyceride, 
were inversely associated with circulating serum vitamin D 
levels. Metabolic syndrome is a very important risk factor for 
cardiovascular disease, which is a major cause of death and 
early mortality in patients with psychosis.12,31,32 In previous 
studies of the general population, vitamin D insufficiency was 
associated with a risk for metabolic syndrome.33-35 Vitamin D 
deficiency is also related to increased risk of hypertension, 
heart failure, and ischemic disease.10 This is the first study to 
demonstrate an association between vitamin D insufficiency, 
metabolic syndrome, and hypertension in an Asian popula-
tion with psychosis. 
Several mechanisms have been proposed to explain the as-
sociation between vitamin D and future risk of metabolic syn-
drome. Since vitamin D is fat soluble and could be stored in 
adipose tissue, the levels of circulating vitamin D can be re-
duced in the blood of obese individuals.35,36 Vitamin D has 
also been shown to inhibit the release of cytokines from the 
immune cell.37 Another hypothesis is the negative regulatory 
effect of vitamin D on renin activity. In an animal study, vita-
min D receptor knockout mice had hypertension, cardiac 
hypertrophy, and increased activation of the renin-angioten-
sin-aldosterone system.38 Mechanism for the association be-
tween vitamin D and cardiovascular risk involves the effect of 
vitamin D on improving insulin sensitivity39,40 by directly act-
ing on cardiac tissue in response to injury41 and vascular com-
pliance and response to injury.42,43 
As this study was cross-sectional, we cannot conclude that vi-
tamin D insufficiency was the cause of metabolic syndrome 
or hypertension. In particular, poor physical activity and di-
etary habits may affect both metabolic syndrome and vita-
min D insufficiency because vitamin D is produced in the 
skin as vitamin D3 through sun exposure or is obtained from 
the diet as vitamin D2 or D3.10 In our study, only 66 patients 
(21.9%) were moderately or highly physically active as mea-
sured by the IPAQ. This is a very low level compared with lev-
els of physical activity measured by the same scale for the gen-
eral populations in 20 other countries.44 Negative symptoms 
of schizophrenia may be related to low physical activity45 and 
sun exposure, and consequently cause a vitamin D insuffi-
ciency. However, in our study, vitamin D level was not differ-
ent according to physical activity or dietary habits. In addition, 
the significant association between vitamin D insufficiency 
and metabolic syndrome remained after adjusting for physi-
cal activity and dietary habits.
Although liver function tests including AST and ALT are 
not diagnostic criteria for metabolic syndrome, liver markers 
have also been implicated in the development of metabolic 
syndrome.46 ALT is correlated with increased hepatic fat con-
Table 2. Logistic regression model for association between vitamin D insufficiency and cardiovascular disease
OR (95% CI) p-value Adjusted OR* (95% CI) p-value
Metabolic syndrome 2.5 (1.3–5.0) 0.007 3.1 (1.5–6.4) 0.003
Hypertension 2.3 (1.1–4.5) 0.019 2.5 (1.2–5.3) 0.013
*adjusted for physical activity and dietary habit scores in the model. OR: odds ratio, CI: confidence interval
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tent, which is associated with insulin resistance regardless of 
body weight. Insulin resistance has detrimental effects on 
components of metabolic syndrome.47-49 Our study showed 
that patients with a vitamin D insufficiency were associated 
with a higher ALT, which indirectly suggests an association 
between vitamin D insufficiency and metabolic syndrome.
Whether vitamin D supplementation decreases cardiovas-
cular risk in the general population or patients with mental 
illness is controversial. Several studies have focused on vita-
min D as a potential anti-hypertensive agent, but they have 
not consistently shown a positive effect.10 Very few studies 
have been performed on whether vitamin D supplementa-
tion reduces the risk of cardiovascular mortality. Both the 
Women’s Health Initiative Study50 and a European study51 
showed no improved cardiovascular survival after vitamin D 
supplementation. On the other hand, a recent meta-analysis 
examined nine randomized controlled trials and showed an 
8% reduction in all-cause mortality with supplementation of 
up to 500 IU vitamin D.10 That study was conducted on a gen-
eral population. Although a few studies have analyzed wheth-
er vitamin D supplementation affects mental health, with the 
largest being negative,52 no research has been conducted on 
the influence of vitamin D supplementation on metabolic 
syndrome and cardiovascular risk in patients with a psychot-
ic disorder. In addition, there is no consensus on the appropri-
ate vitamin D dose for patients with a mental illness. There-
fore, prospective studies are required to define whether vitamin 
D supplementation can reduce the occurrence of metabolic 
syndrome and cardiovascular risk in patients with a psychot-
ic disorder and the appropriate vitamin D dose needed.
Vitamin D level is associated with various mental health 
issues. In particular, low vitamin D level is associated with 
depression.53 However, in our study, low vitamin D level was 
not related to depressive symptoms or the general severity of 
psychotic symptoms.
This study had several limitations. First, this study was cross-
sectional, so we were unable to investigate the causal relation-
ship between vitamin D and metabolic syndrome. Second, 
the assessment of depressive symptoms, dietary habits, and 
physical activity depended on self-reported data. Third, a for-
mal scale to measure psychotic symptoms was not adminis-
terd. Fourth, we did not investigate intake of vitamin supple-
ments. Finally, most of the study population participated in this 
study during late fall and early winter when vitamin D levels 
might be lower than at other times of the year.28,54 In addition, 
amount of sun exposure was not investigated. 
Nevertheless, this study has important clinical and research 
implications by showing that vitamin D insufficiency was very 
prevalent and associated with metabolic syndrome and hy-
pertension in South Korean patients with psychosis. Further 
longitudinal and interventional studies are required in pa-
tients with psychosis. 
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